CN100391375C - Substitute of cigarette contaniing compound nicotine and preparation method - Google Patents
Substitute of cigarette contaniing compound nicotine and preparation method Download PDFInfo
- Publication number
- CN100391375C CN100391375C CNB200510048628XA CN200510048628A CN100391375C CN 100391375 C CN100391375 C CN 100391375C CN B200510048628X A CNB200510048628X A CN B200510048628XA CN 200510048628 A CN200510048628 A CN 200510048628A CN 100391375 C CN100391375 C CN 100391375C
- Authority
- CN
- China
- Prior art keywords
- nicotine
- substitute
- cigarette
- dexamethasone
- menthol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 50
- 229960002715 nicotine Drugs 0.000 title claims abstract description 50
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 235000019504 cigarettes Nutrition 0.000 title claims abstract description 48
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000000391 smoking effect Effects 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 18
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 17
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940041616 menthol Drugs 0.000 claims abstract description 17
- 238000010521 absorption reaction Methods 0.000 claims abstract description 13
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims abstract description 6
- 229960003657 dexamethasone acetate Drugs 0.000 claims abstract description 6
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 15
- 241000180649 Panax notoginseng Species 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 229920002367 Polyisobutene Polymers 0.000 claims description 7
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 6
- 229940116229 borneol Drugs 0.000 claims description 6
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 6
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 6
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 4
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 239000011505 plaster Substances 0.000 abstract 1
- 239000002574 poison Substances 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 239000008678 sanqi Substances 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003546 flue gas Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011269 tar Substances 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000004224 Opium Dependence Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 231100000670 co-carcinogen Toxicity 0.000 description 1
- 239000003142 cocarcinogen Substances 0.000 description 1
- 239000011285 coke tar Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940084954 dexamethasone 1 mg Drugs 0.000 description 1
- 229940084972 dexamethasone 1.5 mg Drugs 0.000 description 1
- 229940097957 dexamethasone 2 mg Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940061254 nicotine 1 mg Drugs 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a substitute for cigarettes containing compound nicotine and a preparation method thereof, which belongs to the technical field of substitutes of cigarettes. The present invention is mainly characterized in that nicotine, menthol, dexamethasone acetate, sanqi powder and medicinal accessories are prepared to be paste directly coated on the surface of skin or is made into a percutaneous absorption plaster bonded on the surface of skin to substitute suction cigarettes. The substitute for cigarettes of the present invention can quickly satisfy the desire of smoking of a smoker, and has the advantages of good product comfort to skin, convenient use, no fireworks and no disadvantage and poison when cigarettes are burnt and sucked. The present invention is an ideal substitute for cigarettes, which is suitable for various places to use.
Description
Technical field
The present invention relates to a kind of cigarette substitute that contains compound nicotine, belong to cigarette and substitute the articles for use technical field.
Background technology
Smoking is harmful to your health has been a undisputable fact.Cigarette mainly comes from cigarette burning to the harm of human body and produces materials such as tar, carbon monoxide, formaldehyde and hydrogen cyanide in the flue gas, wherein the harm maximum of tar.There are some researches show that 0.2% material is strong carcinogenic substance (as 3, condensed-nuclei aromatics compound, nitrosamine etc. such as 4-BaPs) in the coke tar in cigarette, 0.4% material is cocarcinogen or direct harmful substance.Therefore, the smoker is for a long time by burning and sucking the mode smoking of cigarette, not only be harmful to self health, easily cause diseases such as respiratory system, and the environment flue gas that cigarette is discharged when burning and sucking also exists equally surrounding population even bigger harm (particularly to some non-smokers, pregnant woman and children); In addition, also there is the risk of initiation fire in the cigarette of burning.Thereby along with the enhancing of raising, health care and the awareness of safety of people's living standard, modern society is requiring that cigarette manufacturer produces low tar burst size more, harm is littler and during the cigarette of lower fire risk, also progressively limit the smoker through various channels in some public arena smoking, these restrictions usually cause the smoker can not enjoy the due satisfaction of smoking with convenient.
Why smoking of smoker, mainly relevant with contained nicotine in the flue gas.Medically think: absorb the nicotine enter the blood of human body circulatory system by lung during smoking the physiology and the nervous system of human body had mental excitation and psychosedative dual regulation.That is to say, tired out or when having a slow wit as people, smoking can make the people regain one's vigor, clearheaded; And when nervous or irritated, smoking can make people's calmness again, chill out.In addition, prove also that medically nicotine has unique therapeutic action to human parkinsonism, Alzheimer disease and many infirmitiess of age.Thereby the demand to an amount of nicotine kept in smoker's body concerning smoker self, there is no unfavorable, and blindness requires the smoker to give up smoking or it is carried out mandatory ban on opium-smoking and the opium trade, then cause the physiological equilibrium set up for a long time in smoker's body destroyed easily, and and then cause health and psychological incompatibility even many diseases.
Consider above-mentioned factor, thereby provide some non-cigarette substitutes that burn and suck necessary for smoker.At present, the non-cigarette substitute that burns and sucks has: traditional snuff and chewing tobacco, oral administration contain nicotine oral liquid, chewing gum, spray, and the electronics cigarette that gets up of modern development.As everyone knows, traditional snuff and chewing tobacco are that the most of cigarette consumer of China can not accept owing to sucking custom and taste problem; Publication number is respectively CN1553771A, CN1579398A, CN1607950A, and notification number be the Chinese patent of CN1042292C also introduced some oral administration contain nicotine oral liquid, chewing gum and spray, but contained nicotine in the product is owing to have the bitter taste that the oral cavity is difficult to accept, can influence suck mouthfeel, nicotine enters the decomposition that also need go through hydrochloric acid in gastric juice neutralization, liver in the body and just can enter hematological system simultaneously, thereby greatly reduces the effective rate of utilization of nicotine; The electronics cigarette that gets up as for modern development, then because the cost height, cost an arm and a leg, technology is also improved as yet so promoted and use.
In addition, also occur a class in recent years and contain nicotine or not nicotine-containing smoking cessation paster, use these pasters also can play to alleviate or suppress the demand of smoker smoking.But on the one hand the purposes of these pasters is in order to give up smoking, thereby product often contains BUPROPIONE HCl, clonidine, lofexidine, dopamine, dopamine precursor, soloxsalen, makes every effort to overcome the big stop smoking medicine of side effect such as thunder; What these pasters adopted on the other hand is the long-acting slow-release technology, promptly guarantee slowly evenly discharging of nicotine or stop smoking medicine by adding sustained release agents such as azone, long period is alleviated or suppress the demand of smoker to smoking thereby reach, rather than to satisfy the smoker be purpose to the demand of smoking or nicotine to reach rapidly.In addition, these products also ignored paster and skin Long contact time comfort, comprise paster include medicine particularly nicotine to the problem of skin irritation.
Summary of the invention
The object of the present invention is to provide a kind of cigarette substitute that contains compound nicotine.Different with other cigarette substitute or smoking cessation paster is that cigarette substitute of the present invention can be fit to various places to be used, can fast and effeciently satisfy the hope of smoker to smoking.
As follows for realizing the technical measures that purpose of the present invention adopts:
A kind of cigarette substitute that contains compound nicotine is characterized in that: nicotine, menthol, dexamethasone, Radix Notoginseng powder and pharmaceutic adjuvant are mixed with paste directly embrocate at skin surface or make percutaneous absorption patch and be affixed on skin surface, to replace smoking cigarette.
The quality proportioning of nicotine, menthol, dexamethasone, Radix Notoginseng powder and pharmaceutic adjuvant is in the compound: nicotine 5-20g, menthol 0.5-2g, dexamethasone acetate 1-5mg, Radix Notoginseng powder 1-10g, pharmaceutic adjuvant 50-200g.
Preparation is directly embrocated when the paste of skin surface, and employed pharmaceutic adjuvant is an albolene.
When preparation was used to make the paste of percutaneous absorption patch, employed pharmaceutic adjuvant was atoleine and polyisobutene, and wherein the quality proportioning of atoleine and polyisobutene is 1: 6.Then with the preparation paste be Drug Storage, by the manufacture method of known percutaneous absorption patch, make percutaneous absorption patch.
Menthol in the compound is used as quick penetrating agent that promotes nicotine transdermal barrier and the coolant agent that strengthens the skin comfort, also can be in menthol, menthyl ester, the borneol one or more.
Dexamethasone in the compound can alleviate nicotine to the excitant of skin, anti-allergic, also can be in dexamethasone, dexamethasone acetate, the dexamethasone sodium phosphate one or more.
Radix Notoginseng powder in the compound has the skin expansion pore, promotes the local blood circulation, accelerates the effect of nicotine transdermal barrier, also has anti-inflammatory, anti-allergic effect simultaneously, during use pseudo-ginseng is worn into the fine powder below the 75 μ m.
The cigarette substitute of compound nicotine of the present invention, contain nicotine and nicotine is played Synergistic, enhancing skin comfort, antianaphylactic menthol, dexamethasone and Radix Notoginseng powder, thereby in use, but nicotine quick penetration skin barrier enters the blood of human body circulatory system rapidly, satisfies the hope of smoker to smoking fast, and is good to the comfortableness of skin; The cigarette substitute pyrotechnics easy to use, no that contains compound nicotine simultaneously of the present invention, avoided burning and sucking all unfavorable of cigarette and poisoned, manufacture method is simple, with low cost, is the desirable cigarette substitute that a kind of energy is fit to the use of various places.
The specific embodiment
Below in conjunction with specific embodiment technical scheme of the present invention is described further.
Embodiment 1
Behind nicotine 5g, menthol 0.5g, dexamethasone 1mg stirring and dissolving together, add Radix Notoginseng powder 1.5g and medicinal albolene 193g again, stirring promptly, preparation becomes the paste that can directly embrocate at skin surface.
Embodiment 2
Behind nicotine 10g, menthol 0.5g, borneol 0.5g, dexamethasone acetate 3mg stirring and dissolving together, add Radix Notoginseng powder 3g and medicinal albolene 85g again, stirring promptly, preparation becomes the paste that can directly embrocate at skin surface.
Embodiment 3
Behind nicotine 15g, menthyl lactate 1.5g, borneol 1g, dexamethasone sodium phosphate 5mg stirring and dissolving together, add Radix Notoginseng powder 7.5g and medicinal albolene 75g again, stirring promptly, preparation becomes the paste that can directly embrocate at skin surface.
Embodiment 4
Behind nicotine 7.5g, menthol 1g, dexamethasone 1.5mg stirring and dissolving together, add Radix Notoginseng powder 1.5g, atoleine 20g and polyisobutene 120g again, stir into even paste.With the preparation paste be Drug Storage, by the manufacture method of known percutaneous absorption patch, make percutaneous absorption patch.
Embodiment 5
Behind nicotine 10g, menthol 1g, tartaric acid menthyl ester 0.5g, borneol 0.5g, dexamethasone 2mg stirring and dissolving together, add Radix Notoginseng powder 4g, atoleine 12g and polyisobutene 72g again, stir into even paste.With the preparation paste be Drug Storage, by the manufacture method of known percutaneous absorption patch, make percutaneous absorption patch.
Embodiment 6
Behind nicotine 18g, menthol 2g, menthyl lactate 1g, borneol 1g, dexamethasone sodium phosphate 4mg stirring and dissolving together, add Radix Notoginseng powder 8g, atoleine 10g and polyisobutene 60g again, stir into even paste.With the preparation paste be Drug Storage, by the manufacture method of known percutaneous absorption patch, make percutaneous absorption patch.
Table 1 has been listed the cigarette substitute of above each embodiment when test dose is 40mg, is used the average onset time of being tested by different smoking degree crowds.As seen use the cigarette substitute that contains compound nicotine by the inventive method preparation, can reach and satisfy the purpose of smoker fast the smoking hope, simultaneously the cigarette substitute is good to the comfortableness of skin in use, product is easy to use, no pyrotechnics, avoided burning and sucking all unfavorable of cigarette and murder by poisoning, manufacture method is simple, with low cost, is that a kind of energy is fit to the desirable cigarette substitute that use in various places.
The cigarette substitute test effect of each embodiment of table 1
| The cigarette substitute | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 |
| Nicotine content | 2.5％ | 10％ | 15％ | 5％ | 10％ | 18％ |
| Test dose | 40mg | 40mg | 40mg | 40mg | 40mg | 40mg |
| Every dose of nicotine | 1mg | 4mg | 6mg | 2mg | 4mg | 7.2mg |
| The test crowd * | Slight smoking | Moderate smoking | Severe smoking | Slight smoking | Moderate smoking | Severe smoking |
| Average onset time | 5.6min | 4.5min | 4.0min | 5.1min | 4.8min | 4.1min |
Annotate: slight smoking, moderate smoking and heavy smoker in the table in the test crowd hurdle are respectively average daily suction
The cigarette amount below 15,15-30 props up, and crowd more than 30.
Claims (7)
1. cigarette substitute that contains compound nicotine is characterized in that: nicotine, menthol, dexamethasone, Radix Notoginseng powder and pharmaceutic adjuvant are mixed with paste directly embrocate at skin surface or make percutaneous absorption patch and be affixed on skin surface, to replace smoking cigarette.
2. the cigarette substitute that contains compound nicotine according to claim 1, it is characterized in that: the quality proportioning of nicotine, menthol, dexamethasone, Radix Notoginseng powder and pharmaceutic adjuvant is: nicotine 5-20g, menthol 0.5-2g, dexamethasone acetate 1-5mg, Radix Notoginseng powder 1-10g, pharmaceutic adjuvant 50-200g.
3. the cigarette substitute that contains compound nicotine according to claim 1 and 2 is characterized in that: preparation is directly embrocated when the paste of skin surface, and employed pharmaceutic adjuvant is an albolene.
4. the cigarette substitute that contains compound nicotine according to claim 1 and 2, it is characterized in that: when preparation is used to make the paste of percutaneous absorption patch, employed pharmaceutic adjuvant is atoleine and polyisobutene, and wherein the quality proportioning of atoleine and polyisobutene is 1: 6.
5. the cigarette substitute that contains compound nicotine according to claim 1 and 2 is characterized in that: described menthol can be one or more in menthol, menthyl ester, the borneol.
6. the cigarette substitute that contains compound nicotine according to claim 1 and 2 is characterized in that: described dexamethasone can be one or more in dexamethasone, dexamethasone acetate, the dexamethasone sodium phosphate.
7. the cigarette substitute that contains compound nicotine according to claim 1 and 2 is characterized in that: described Radix Notoginseng powder is that pseudo-ginseng is worn into fine powder below the 75 μ m.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510048628XA CN100391375C (en) | 2005-11-15 | 2005-11-15 | Substitute of cigarette contaniing compound nicotine and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510048628XA CN100391375C (en) | 2005-11-15 | 2005-11-15 | Substitute of cigarette contaniing compound nicotine and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1759770A CN1759770A (en) | 2006-04-19 |
| CN100391375C true CN100391375C (en) | 2008-06-04 |
Family
ID=36706095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510048628XA Expired - Fee Related CN100391375C (en) | 2005-11-15 | 2005-11-15 | Substitute of cigarette contaniing compound nicotine and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100391375C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751060B (en) * | 2014-01-21 | 2016-03-30 | 江苏中烟工业有限责任公司 | A kind of moist humidity-preserving type tobacco gel composition composition and method of making the same |
| CN103751252A (en) * | 2014-01-21 | 2014-04-30 | 江苏中烟工业有限责任公司 | Antiseptic disinfectant wash-free type tobacco gel composition and preparation method thereof |
| CN103767062B (en) * | 2014-01-21 | 2016-04-27 | 江苏中烟工业有限责任公司 | A kind of anti-blooming antiemetic type tobacco gel composition and preparation method thereof |
| CN104305516B (en) * | 2014-08-25 | 2016-08-31 | 上海烟草集团有限责任公司 | The SMD smoke-free tobacco product in a kind of oral cavity |
| CN106579540A (en) * | 2016-12-30 | 2017-04-26 | 中国烟草总公司广东省公司 | Ointment type past cigarette and preparation method |
| CN106579539A (en) * | 2016-12-30 | 2017-04-26 | 中国烟草总公司广东省公司 | Fresh-scent type smokeless tobacco product and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1180500A (en) * | 1996-10-25 | 1998-05-06 | 黄筑亮 | Snuff and its manufacture technique |
| CN1555231A (en) * | 2001-05-01 | 2004-12-15 | ��R��˹����ķ | Smokeless tobacco product |
-
2005
- 2005-11-15 CN CNB200510048628XA patent/CN100391375C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1180500A (en) * | 1996-10-25 | 1998-05-06 | 黄筑亮 | Snuff and its manufacture technique |
| CN1555231A (en) * | 2001-05-01 | 2004-12-15 | ��R��˹����ķ | Smokeless tobacco product |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1759770A (en) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100391375C (en) | Substitute of cigarette contaniing compound nicotine and preparation method | |
| JP5845194B2 (en) | Nicotine-containing soft gelatin troche | |
| WO2021003467A1 (en) | Metered dosing compositions and methods of use of psychedelic compounds | |
| RU2436565C2 (en) | Disintegrating oral films | |
| ES2605244T3 (en) | Nicotine Pill Compositions | |
| EP1666030B1 (en) | Improved nicotine lozenge and therapeutic method for smoking cessation | |
| RU2279871C2 (en) | Liquid pharmaceutical composition comprising nicotine for administration into mouth cavity | |
| US6358060B2 (en) | Two-stage transmucosal medicine delivery system for symptom relief | |
| US20110268809A1 (en) | Nicotine-Containing Pharmaceutical Compositions | |
| JP3210945B2 (en) | Smoking alternatives | |
| KR20090024161A (en) | Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent | |
| CN104114151A (en) | Excipients for nicotine-containing therapeutic compositions | |
| JP2010526876A (en) | Coated oral nicotine formulation buffered by amino acids | |
| WO1996000072A1 (en) | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine | |
| CA3096580C (en) | Compositions infused with nicotine compounds and methods of use thereof | |
| MXPA04012041A (en) | A buffered, liquid nicotine composition for pulmonary administration. | |
| KR20140108728A (en) | Solid nicotine-comprising dosage form with reduced organoleptic disturbance | |
| US20170007594A1 (en) | Therapeutic composition and configuration | |
| CN101437497A (en) | Stable lozenge compositions providing rapid release of nicotine | |
| US20100233244A1 (en) | Smoking Withdrawal Combination Wafer | |
| JP2677371B2 (en) | Hydrous smoking substitute patch | |
| RU2745039C1 (en) | Nicotine edible paper | |
| CA3198464A1 (en) | Rapidly infusing compositions and methods | |
| CN103040835B (en) | A kind of Pharmaceutical composition containing sildenafil citrate and preparation method thereof | |
| WO2015068058A1 (en) | Tobacco free 'niconuts'and the process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN REASCEND TOBACCO TECH. (GROUP) CO., LTD. Free format text: FORMER OWNER: CHEN HUIMIN Effective date: 20140403 Free format text: FORMER OWNER: QIU YE Effective date: 20140403 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140403 Address after: 650106 Yunnan province Haiyuan Kunming high tech Development Zone No. 1699 North Road Patentee after: Yunnan Reascend Tobacco Technology (Group) Co., Ltd. Address before: 650106 No. 41, medical Road, hi tech Development Zone, Yunnan, Kunming Patentee before: Chen Huimin Patentee before: Qiu Ye |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160621 Address after: 650106 Yunnan city of Kunming province high tech Zone Haiyuan Road No. 1699 Patentee after: YUNNAN TUOBAO SCIENCE & TECHNOLOGY CO., LTD. Address before: 650106 Yunnan province Haiyuan Kunming high tech Development Zone No. 1699 North Road Patentee before: Yunnan Reascend Tobacco Technology (Group) Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080604 Termination date: 20171115 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |